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Abstract: Background: The COVID-19 pandemic and the related lockdown measures presented a 
signifcant risk to physical and mental wellbeing in affected populations. Women with polycystic 
ovary syndrome (PCOS) are predisposed to several cardio-metabolic risk factors which increase the 
susceptibility to severe COVID-19 and also exhibit increased likelihood of impaired mental health 
wellbeing. Therefore, these women who usually receive care from multiple primary and specialist 
healthcare services may be disproportionately impacted by this pandemic and the related restrictions. 
This study aimed to explore the lived experience of the frst UK national lockdown as a woman with 
PCOS. Methods: As part of a larger cross-sectional study, 12 women with PCOS living in the UK dur-
ing the frst national COVID-19 lockdown were recruited to a qualitative study. Telephone interviews 
were conducted in June/July of 2020, and data collected were subjected to thematic analysis. Results: 
Five themes were identifed. “My PCOS Journey” describes participants’ experiences of diagnosis, 
treatment and ongoing management of their PCOS. “Living Through Lockdown” describes the 
overall experience and impact of the lockdown on all aspects of participants’ lives. “Self-care and 
Managing Symptoms” describe multiple challenges to living well with PCOS during the lockdown, 
including lack of access to supplies and services, and disruption to weight management. “Healthcare 
on Hold” describes the uncertainty and anxiety associated with delays in accessing specialised 
healthcare for a range of PCOS aspects, including fertility treatment. “Exacerbating Existing Issues” 
captures the worsening of pre-existing mental health issues, and an increase in health anxiety and 
feelings of isolation. Conclusion: For the women with PCOS in this study, the COVID-19 pandemic 
and the frst national lockdown was mostly experienced as adding to the pre-existing challenges of 
living with their condition. The mental health impact experienced by the study participants was 
increased due to lack of access to their normal support strategies, limitations on healthcare services 
and uncertainty about their risk of COVID-19. 
J. Pers. Med. 2021, 11, 952. https://doi.org/10.3390/jpm11100952 https://www.mdpi.com/journal/jpm 
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1. Introduction 
In March 2020, the World Health Organization (WHO) declared a pandemic outbreak 
of the Coronavirus Disease-2019 (COVID-19) [1,2], caused by the severe acute respira-
tory syndrome coronavirus-2 (SARS-CoV-2) [3,4]. Most COVID-19 cases remain asymp-
tomatic or mild, but severe symptoms and complications may develop in a proportion of 
predisposed/high-risk patients [3,4]. Due to this risk of severe and even fatal COVID-19, 
governments and relevant public health authorities worldwide enforced nationwide lock-
down/quarantine measures, aiming to decrease the transmission of SARS-CoV-2 among 
the general population, and hence protect the health of vulnerable individuals [4–7]. Based 
on robust clinical and epidemiological evidence, it is now clear that, in addition to older 
age and male sex, susceptibility to severe COVID-19 is directly associated with a number 
of chronic cardio-metabolic diseases, such as obesity, diabetes, hypertension and metabolic 
syndrome [8–14]. Of note, with the exception of advanced age and male sex, the same 
cardio-metabolic risk factors which predispose to severe COVID-19 are also highly preva-
lent among women with polycystic ovary syndrome (PCOS) [15,16], placing this female 
patient population at potentially increased risk during the COVID-19 pandemic [17]. 
PCOS represents the most frequent endocrine disorder among women of reproduc-
tive age, with reported prevalence rates of 10–15% or even higher, depending on the 
utilised diagnostic criteria and the studied population/country [15,16]. Prominent fea-
tures/symptoms of PCOS include ovarian dysfunction with chronic oligo-/anovulation 
and hyperandrogenism (either clinical with hirsutism, acne and androgenic alopecia, 
and/or biochemical with high circulating testosterone/androgen levels), whilst polycystic 
ovary morphology on ultrasound scanning may be also present [15,16,18]. As aforemen-
tioned in the majority of women with PCOS, obesity and a constellation of obesity-related 
comorbidities (e.g., type 2 diabetes (T2DM) and obstructive sleep apnoea (OSA)) compli-
ment the common presenting PCOS phenotypes [15,16,19,20]. Of further importance, PCOS 
management in routine clinical practice is typically fragmented between multiple health-
care services and specialities, including general practitioners (GPs), gynaecologists, infertil-
ity specialists, endocrinologists and dermatologists [16,21], whilst it is also characterised by 
marked gaps regarding prompt diagnosis and appropriate management/treatment [22,23]. 
To date, despite the high prevalence of PCOS and the potentially high risk of these pa-
tients for severe COVID-19 [17,24,25], there is a paucity of research on the potential effects 
of the COVID-19 pandemic and the related lockdown/quarantine measures on this female 
population. However, previous published qualitative research which explored the lived 
experience of PCOS has highlighted some aspects that are likely to be relevant to living with 
this chronic health condition through the circumstances posed by the COVID-19 pandemic. 
These include feelings of difference and isolation from “normal” women [26,27]; percep-
tions of their condition not being adequately addressed by their GPs/doctors; diffculties 
accessing specialist healthcare services, including fertility and mental health services [28]; 
and the importance of emotional support from both family/friends and healthcare profes-
sionals in coping with the psychological distress caused by the condition [29]. Additionally, 
qualitative research consistently documents unremitting and draining struggles to control 
body weight [28], frustration and diffculties in getting answers to questions about their 
condition and symptoms [30], and negative impacts on their work, social interactions and 
romantic relationships [29]. As such, the objective of the present study was to capture the 
unique patient experiences of women with PCOS during the pandemic lockdown, by ob-
taining novel qualitative data addressing the research question of; “What is the experience 
of living through the COVID-19 pandemic lockdown restrictions in the United Kingdom 
(UK), as a woman with PCOS?”, in order to better inform the clinical practice in primary 
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and specialist care regarding the respective management needs and issues identifed as 
important by these patients during this disrupting period. 
2. Materials and Methods 
2.1. Study Design 
This qualitative interview study was nested within a cross-sectional online sur-
vey/study, which aimed to examine a range of physical and psychological effects of 
the COVID-19 pandemic on women with PCOS, as previously described [31]. The aim of 
including a qualitative element to this study was to elucidate the quantitative fndings, and 
to provide further insight into the experience of living with PCOS during this pandemic 
and its associated restrictions. As such, a target to recruit 12 women was set for the present 
qualitative interview study as a suffcient sample size to provide data on a range of experi-
ences, while minimising participant burden. Ethical approval was granted by the ethics 
committee of Coventry University (ref. number: P106195) and all participants provided 
consent for their participation in this study. 
2.2. Study Participants 
In total, 12 women were interviewed for the present study. All women reported 
having received a diagnosis of PCOS. The ages of the study participants ranged from 24 
to 42 years. Two participants identifed as Asian, and all others as White. The reported 
body mass index (BMI) ranged from 22.6 to 53.6 kg/m2, with ten participants reporting a 
current BMI over 30 kg/m2 (coexisting obesity). Further details about the participants are 
presented in Supplementary Materials Table S1. 
2.3. Study Procedure 
Participants were recruited via the online study survey. Following informed consent, 
information regarding the present interview study was provided after completion of the 
survey questions, using the survey software, Qualtrics© XM (Qualtrics XM, Provo, UT, 
USA). Participants indicated specifc consent to be interviewed via an additional form 
within the survey, presented after the relevant participant information. Details of all survey 
participants who indicated willingness to take part in an interview were passed to the lead 
author. In order to maintain anonymity, a mobile phone number was the only personal 
information collected from the survey participants, and subsequently participants were 
invited for an interview via SMS text messaging. The list of consented participants was 
worked through in date order until 12 participants had been recruited and interviewed. 
2.4. Data Collection 
Data collection took place between 8 June and 1 July 2020. Interviews were conducted 
by phone at a time agreed with the participant via text messaging. Telephone interviews 
are well suited to qualitative studies such as the present study, where the primary aim is to 
gather more detailed data pertaining to topics explored quantitatively [32] and have been 
shown to be an effective method of data collection, with some advantages over face-to-face 
interviews [33]. Additionally, face-to-face interviews would have been neither safe nor 
legal due to the stage of the pandemic response in the UK at that time. Telephone interviews 
also enabled participants to maintain their anonymity, which may not have been assured if 
video conferencing had been used. Interviews were audio recorded following consent by 
the participant and were then transcribed verbatim. All interviews were conducted by the 
lead author, a very experienced qualitative researcher specialising in women’s health. A 
topic guide was devised to explore the same topics as the quantitative questions, and this 
was used to guide each interview, although participants were encouraged to speak freely 
about anything they felt was relevant to their experiences. Duration of interviews ranged 
from 16 to 38 min, with a mean duration of 24 min. 
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2.5. Data Analysis 
Data were imported into NVivo© (QSR International Pty Ltd., Chadstone, VIC, Aus-
tralia) and analysed by the lead author using a process of inductive thematic analysis, 
following the principles outlined by Braun and Clarke [34]. In brief, the process involved 
initial familiarisation, via multiple readings of the transcripts, where initial thoughts about 
patterns within the data were noted. This was followed by line-by-line examination of 
each transcript, where all elements relevant to the research questions were identifed and 
assigned a code, in order for extracts relating to the same subject to be collated together. 
Codes were then grouped together into initial themes, which were then checked against the 
dataset and refned, to produce a thematic map. Finally, themes were named and described, 
and data extracts were selected to illustrate the fnalised themes. A realist approach was 
taken to data analysis, where data were treated as refecting the participants’ reality, a 
priori knowledge and assumptions were set aside, and data were coded according to the 
prevalent ideas and content within. 
3. Results 
Five main themes were derived from the study dataset. These are briefy summarised 
in Figure 1. One theme, “Living Through Lockdown”, describes the experience of the 
pandemic and lockdown that were not specifc to having PCOS. Another theme, “My 
PCOS Journey” describes participants’ experience of their condition prior to the pandemic, 
including symptoms, diagnosis, treatment and the social and emotional impact of the 
condition. While these themes offer important context, they will only be described briefy 
in order to focus on the remaining themes which describe the more unique experiences of 
living through the COVID-19 pandemic and lockdown as a woman with PCOS. These are: 
“Self-care and Managing Symptoms”, “Healthcare on Hold”, and “Exacerbating Existing 
Issues”. 
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3.1. My PCOS Journey 
Every participant’s experience of PCOS was unique, but between the 12 interviewed 
participants the broad spectrum of PCOS symptoms was described, including absent, 
irregular and/or heavy and painful menstrual periods, diffculties with increased body 
weight and weight management, acne, excess hair growth, low energy, uncontrollable 
emotions, and low mood or depression. Of note, while some women reported being “so 
J. Pers. Med. 2021, 11, 952 5 of 15 
lucky” (P5) to have had no problems conceiving, others had been unsuccessful when trying 
to conceive naturally, and the majority reported worrying about their chances of having 
children, either presently or prior to conceiving. 
“when I found out that I only ovulated from one ovary I sat and cried . . . I was terri-
fed.” (P8) 
Moreover, a range of PCOS diagnosis experiences were reported. Some women 
experienced symptoms for years before being diagnosed, which was a source of frustration, 
as they commonly felt that they knew something was “wrong”. In contrast, among the 
participants who were diagnosed as a teenager or very young woman, several reported 
feeling disappointed with their healthcare experience following diagnosis. This included 
simply being prescribed the contraceptive pill, told not to worry, and/or being told they 
might struggle to conceive and to come back when they were ready to have children. 
Descriptions of struggles to get support and treatment from healthcare professionals 
were common among participants, as were reports of having to push for and/or try 
different medications before fnding an effective treatment for specifc symptoms. 
“No one’s offered me an endocrinologist or a dermatologist I’ve just been told it’s not bad 
enough. And I was like well who are you to say it’s not bad enough? It’s bad enough for 
me.” (P5) 
To these experiences, women often described searching elsewhere for information and 
treatment options and trying their own strategies to manage their condition. 
“the last couple of years I’ve spoken to a lot of other women, become a lot more knowl-
edgeable I suppose, self-educated about it, probably more so in the last year . . . I was also 
trying to change my diet a bit during that time as well, I looked into supplements and 
things like that so probably since about August/September I’d start making some gradual 
changes in that respect as well, just sort of educating myself a bit more in the absence of 
any doctors.” (P2) 
One of the challenges most commonly reported was with trying to lose weight, with 
11 of the 12 participants describing an ongoing battle with their body weight. Some 
participants had been successful at losing weight and reported improvement in symptoms 
and quality of life as a result. However, others felt that nothing they tried had worked or 
perceived that the effort and restrictions required to maintain weight loss were much higher 
than for women who do not have PCOS, and therefore much more diffcult to sustain. 
“I’ve done bootcamps, I’ve done the meal replacement diets, with varying success. Ten 
years ago, I managed to lose 8 stone because I didn’t eat any food other than the meal 
replacement packs for about six months. And it was fne, and it worked brilliantly, it was 
fantastic and there was a lot of symptoms cleared up and it was fab. They do really work 
and I’m trying it again actually and I lost 5 pounds last week, but its balance, you know 
sometimes I just want to be normal.” (P9) 
Women frequently identifed their weight, acne and hair growth as causes of the 
far-reaching psychological and social aspects of having PCOS, including low self-esteem, 
low sex drive and challenges with socialising or relationships. This was in addition to 
experiencing low mood and heightened emotions. As a result, many participants described 
how the accumulation of symptoms of PCOS had a signifcant detrimental and enduring 
effect on their mental health. 
“if it’s not the acne it’s the scars . . . and if it’s not that, it’s my weight and if it’s not that 
it’s the hair. If it’s not that it’s my mood, do you know what I mean, it’s like this spider 
web of things and you can’t sort fnd your way out of it.” (P10) 
3.2. Self-Care and Managing Symptoms 
This theme describes the practical and emotional impact of lockdown restrictions in 
relation to participants’ ability to manage their PCOS symptoms and engage in self-care. 
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3.2.1. Access to Supplies and Services 
The closure of shops, travel restrictions and worry about exposure to the coronavirus 
made it diffcult for some women to access key supplies and services. These included sani-
tary products, medication, healthy food, dietary supplements and hair removal services. 
“when you’ve got access to shops, and chemists if you’re relying on long term medication, 
or if you’re struggling with certain menstrual problems accessing things like sanitary 
pads and stronger painkillers that’s been quite diffcult, that’s been quite a challenge . . . 
if Tesco’s don’t have them in stock or if you’re not in an area where the pharmacy is going 
to deliver to you, that kinda thing, that’s been quite diffcult.” (P11) 
“to begin with, food was like, it was hard to get hold of, do you know what I mean? 
You just sort of, bought what you could to keep you going and that included a lot of 
things that were, processed do you know I mean, like sausage rolls and all the bits in the 
cupboard.” (P10) 
Women also reported that the inability to access exercise facilities, such as gyms, pools 
and classes, along with decreased physical activity due to travel restrictions and changes 
to daily routines, had severely impacted their ability to manage their physical and mental 
symptoms. 
“I would say not being able to do as much exercise. So, for example I can’t go to the gym, 
so that affects my weight as well as my mood. Not being able to go out as much affects 
my mood.” (P7) 
For many participants, there was signifcant concern that their weight loss/ 
management journey would be disrupted as a result of these changes. 
“I just didn’t want to go backwards in my weight loss plans and worsen my PCOS 
symptoms.” (P1) 
“I have gained three quarters of a stone since lockdown started, which is incredibly 
frustrating.” (P5) 
“I would say, yeah it’s made me want to comfort eat more if I’m honest. It just makes me 
want to comfort eat more, I think with me anyway, growing up with PCOS I found it 
really diffcult in terms of some of the symptoms, especially the excess hair and I feel like as 
a coping mechanism I would comfort eat. And I stopped doing that, but now it’s coming 
back again because of the pandemic, and the anxiety around how life is changing in all 
these different ways. So I feel like I’m going back to using unhealthy coping strategies 
again. Sometimes you just don’t feel like making an effort with your appearance, coz 
you’re not going out either.” (P7) 
An inability to access social support was also highlighted as detrimental to managing 
the mental health effects of PCOS during lockdown. 
“And in terms of the, just like emotions being able to get out and have a breather. Being 
able to talk to my friends and my family about these issues I can’t really do that, like see 
them face to face I can’t do that, go out and do that.” (P7) 
3.2.2. Freedom from Usual Pressures 
A number of study participants noted positive impacts of the disruption to their usual 
daily lives. These included being more able to rest and to manage symptoms when working 
from home, as well as establishing new exercise and eating routines. 
“at the start you had kinda less access to certain foods, a lot less access to shops so that’s 
helped a bit this managing my health and wellbeing a bit. You’ve got to make more kinda 
smarter choices about what you’re eating I suppose. Walking everywhere as well instead 
of being able to use public transport so easily, so that’s helped a bit.” (P11) 
“I had like a couple of days where I’ve been really stressed and I’ve had like a bit of 
bleeding, but I’m alright because you know I can change like every hour. But when I’m at 
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work or whatever I can’t and I need to have days off work. But when I’m at home I’m 
okay, well I think I am!” (P6) 
Some women noted that they had had more time to do research and to think about 
their condition and their management of it. This break from the usual daily routine had 
also facilitated a change in some women’s perspectives of their lives and conditions. 
“I know I have been looking at diets and things more and trying to consider, like after 
all of this has happened, and I’m in a better state of mind to think about how I’m gonna 
consume food more... And I don’t know that if before all of this, I would have really sat 
and thought about it. For so much time.” (P8) 
“it’s given me a drive to actually lose weight, which is always good. And maybe speak to 
people more when I’m struggling.” (P12) 
Of note, some women reported a reduction in anxiety as a result of not socialising, 
mostly due to the perceived stigma and social pressure associated with overweight/obesity 
and not meeting societal “beauty standards”. 
“If anything, I think it’s been quite good in the sense that I’ve been a little bit less paranoid 
about having to do things like hair removal and that kind of stuff, because I’m not going 
out as much. So, it’s removed some of that social anxiety regarding it.” (P5) 
3.3. Living through Lockdown 
Most study participants had switched to working from home, as had some of their 
partners, whilst those with children were also home schooling. The majority of participants 
were living with their partner and any children they had, while a few had moved back 
to their family home or that of their partner during the lockdown. Associated with these 
working and living arrangements, participants reported a range of negative social and 
emotional impacts. These included feeling lonely, isolated from friends and family, and a 
sense of not being able to escape the small world to which they were restricted. 
“I’ve got no choice really but to stay indoors more, so I think that’s . . . it’s frustrating. I 
think that emotionally can take a toll on you, sometimes I feel like socialising with, say 
like family members like my mum or dad and I don’t get to see them which makes me feel 
a bit isolated. And its little things like going to the shops and things because you feel 
more anxious about the time going, I just feel very anxious. And I think that can, and 
when you feel anxious and you are changing the way you live it makes me feel a bit like 
low mood as well. So yeah I think that’s it.” (P7) 
Participants also described increased stress levels, poorer sleep, and worry about the 
coronavirus, both personally and for loved ones, making statements such as: “when there’s 
a lot of people dying and you hear about those people that have got the virus I do think, it is a scary 
situation” (P3); and “For myself I’m not worried about it, but for my family I am.” (P9) 
3.4. Healthcare on Hold 
Participants described experiencing reduced access to healthcare professionals and 
services during the COVID-19-related lockdown. This included access to their usual 
clinicians, as well as delays to services they were waiting to receive pre-pandemic. Both 
of these experiences were sources of signifcant anxiety and distress for these women, 
delaying them from further understanding and overcoming/managing their symptoms. 
“I had a period this week and because it was quite heavy and painful, I had phoned the 
GP surgery and I’d said if I could be given something like tranexamic acid even, just 
to make things a bit more manageable, but to actually get that help, you have to fll out 
an online form for the surgery, who then discuss it with the doctor, and then the doctor 
tells the receptionist what to do, then the receptionist phones me back, but they said that 
process could take up to three to four weeks, so that, yeah you feel that you can’t get the 
advice you would normally get at all.” (P11) 
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“I’m not able to be in touch with my doctor as much as I’d like, because she gives me some 
really good advice on things that she thinks will help, and obviously everybody is like 
drowning into the doctor’s system, so it’s really diffcult to see anyone. And I absolutely 
adore my doctor she’s been amazing to me.” (P8) 
Women who were waiting for fertility treatment found this particularly frustrating, as 
they had often been working towards getting that treatment for a long time. 
“We’re waiting on an appointment for [fertility] treatment . . . , just before it happened 
and now everything’s put on hold . . . When you ring up to fnd out anything it’s just 
automated message that says we’ll come back to you, and it’s really hard coz we’ve already 
waited two and a half years to get to this point in March, and it’s just been pulled from 
under our feet again.” (P4) 
Additionally, there was concern from some women that if they needed healthcare in 
the future, including fertility treatment, this would be much more diffcult to access. 
“I thought about things like, if in the future I needed IVF because maybe I might fnd it 
diffcult to get pregnant, in the future maybe because of my PCOS because I know these 
things can change. How would that work out, in terms of me being able to do that? It 
made me think about accessing, for example accessing like GP support really around my 
PCOS, I can’t just go to the doctor and see someone face to face.” (P7) 
3.5. Exacerbating Existing Issues 
For many participants, the pandemic worsened their pre-existing mental health issues. 
Indeed, several participants described anxiety about the coronavirus, stress of a changed 
working environment, fnancial issues and being in constant close proximity to others in 
their household as exacerbating their mood swings, anxiety and depression. 
“at home it is not really somewhere I can relax and I’m very tense and very anxious and a 
lot of that is to do with my mood and my depression that I get with my PCOS symptoms. 
So obviously spending all of my time at home and not being able escape and to go the 
gym or several dog walks a day or whatever I was fnding it really hard, and I was kind of 
going backwards in a lot of things.” (P1) 
“with me having so much time on my hands to think. There are times, you know over the 
last three months where I’ve had to sort of have a word with myself, do you know what I 
mean and sort of turn myself off and tell myself to calm down, sort of talk myself out of it, 
you know because that, that panic is just bubbling underneath, just there you know, and 
it’s like, the bars only gotta be shortened a little bit before it explodes, you know so it’s 
very hard.” (P10) 
Additionally, a few participants mentioned that they felt more vulnerable to the 
coronavirus because of their PCOS or were uncertain as to whether they were at more risk. 
“I am really worried about catching it, like cos I haven’t seen a lot of things, you know 
like regarding PCOS and the virus so I would like to have seen a bit more things about it, 
because obviously there is quite a few women with it, they wouldn’t have seen as well 
which is really worrying like, am I gonna get it. I know you can’t tell if you’re going to 
get it really bad, but are we in that category where it could be really bad?” (P6) 
Although one woman refected that living with a chronic condition may have prepared 
her for the pandemic experience, she also felt vulnerable. 
“I think in that sense, the pandemic in some ways is easier to cope [with] because you’re 
sort of used to that level of restriction on your life anyway, but in other ways, I think 
it can be much more frightening as well because you realise that you’re probably one of 
those people who’s going to be a bit more vulnerable to that virus, and more vulnerable to 
not being able to access healthcare so easily as well, so I think it’s yes, there’s both kind of 
a positive side of having the sort of long term health issue, it can have a positive infuence 
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on how you cope with this kind of situation, but it has quite a negative one as well, it’s 
kind of pretty mixed.” (P11) 
Whether due to a sense of increased vulnerability, or through more general caution 
about protecting themselves and their families from COVID-19, many participants de-
scribed severely limiting their social contact during the lockdown. This had inevitably 
increased the sense of isolation and separation from the social world which many had 
reported when describing their pre-pandemic PCOS journey. 
“we may try and socially distantly see my parents in the next few weeks. But we’ve not 
seen them at all, they’re over in Yorkshire so we would have had to drive to see them so it 
wasn’t an option anyway until recently, and we’ve sort of held back on that a bit longer. 
But yeah certainly keeping in touch with everyone, I just think that “I know my friends 
aren’t seeing each other separately anyway” we’re all sort of spread out and things, so I 
don’t feel that I’m missing out on things that, that my friends are doing, same with my 
family. So yeah, it’s always been fne really yeah, I’ve had days where I’ve felt a little bit 
down. I suppose, you just get a bit cabin fever.” (P2) 
“I think I’ve been out four times since lockdown began, which has impacted my mental 
health quite a bit.” (P8) 
4. Discussion 
The women in this study described a “PCOS journey” which mirrored the lived 
experiences of PCOS documented in previous research. This includes frustration with 
primary care services including late diagnosis [29], diffculties accessing treatment and 
lack of support from healthcare professionals post-diagnosis [28]. As other research has 
also found, the study participants described signifcant and enduring diffculties in los-
ing/managing body weight [28], as well as a wide range of mental health issues and 
detrimental impacts on relationships, work and social lives [29]. Most notably, in line with 
prior research fndings, the participants in this study also described feeling isolated and 
different from other women [26,27] before being physically isolated by restrictions on social 
contact. The women in this study reported aspects of ”living through lockdown” that 
have also been reported within the general UK population’s experiences of the COVID-19 
pandemic. These included loneliness [35], missing face-to-face contact with friends and 
family [36], disruption of normal routines [37], anxiety for their own and others’ health [37], 
and feelings of distress or depression as a result of feeling trapped or claustrophobic by the 
restrictions [36]. 
Uniquely, the participants in this study revealed the impact of the pandemic and 
lockdown restrictions on them as women with PCOS. This included changes to how 
they ”managed symptoms and self-care”, experienced delays and uncertainty due to 
”healthcare on hold”, and particularly in relation to emotional wellbeing and mental 
health, an ”exacerbation of pre-existing issues”. Within these experiences, some potentially 
positive impacts can be identifed; of note, a few women had felt a freedom from pressure 
to achieve a certain aesthetic, as they were not being seen by many people outside of 
their household. Previous studies have identifed that women with PCOS who experience 
visible symptoms/signs, such as hirsutism, acne or obesity, report feeling that they “lack 
femininity” or “feel ugly” [26,27]. In turn, this can lead to low self-esteem and eating 
disorders [38] and can also be a signifcant barrier to engaging in physical activity in 
public settings [39]. However, this reduction in social anxiety is likely to provide only 
temporary relief until restrictions on social contact are removed and social interactions 
become more frequent. Homeworking was also identifed as positive for some women 
in managing their PCOS, as it gave them fexibility to rest or take a break from work 
in response to their symptoms. Early indications are that many employees will be able 
to continue with some element of fexible working or homeworking once government 
guidance to work from home has been lifted [40], which may provide some women 
with PCOS a working environment that better enables them to manage their symptoms; 
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although, downsides of homeworking (e.g., prolonged social isolation and an inability 
to detach from work) should be well-considered and mitigated in this context prior to 
decisions for future homeworking arrangements [41]. Additionally, some participants 
reported that the lockdown had afforded them time to research PCOS management, or an 
opportunity to reconsider their own approach to PCOS management, including making 
positive lifestyle changes. This could lead some women to emerge from this pandemic 
with an improved quality of life in relation to their PCOS. Nevertheless, this has once again 
highlighted that many women with PCOS feel that adequate primary healthcare services 
are lacking and that they are solely responsible for working out how best to manage and 
improve their condition. 
Despite these few prospective positive outcomes, overall, the fndings of the present 
study paint a picture of a very challenging experience for women with PCOS during the 
pandemic and lockdown restrictions. Immediate impacts included the distress experienced 
as a result of diffculties in readily purchasing sanitary products and pain medication as 
needed. The irregularity of menstruation that is a common symptom of PCOS increases 
the likelihood that these participants would require supplies with little or no warning, 
and this combined with the often heavy and painful periods experienced by women 
with PCOS resulted in much more than a minor inconvenience for these participants. 
Of further concern is the worsening of mental health reported by many participants. 
Participants described how the low mood or mood swings, anxiety and/or depression 
they experienced as part of their PCOS had become worse during the COVID-19 pandemic. 
Prior research has identifed that the women with PCOS are more likely to experience 
depression, anxiety and perceived stress than women without PCOS [42], and that the 
majority of women with PCOS experience mental health symptoms [28]. Participants in 
this study attributed a worsening of these symptoms partly to reduced access to social 
support, and previous research has identifed emotional support from friends, family and 
other women with PCOS as an important coping strategy [29]. However, some participants 
also highlighted feelings of vulnerability to the coronavirus, or uncertainty about their 
level of risk based on their condition. PCOS is not mentioned as a condition that may 
increase risk or require “shielding” by any of the UK government coronavirus guidance 
issued in 2020. Yet, conditions that are highly prevalent within the female population 
with PCOS, such as obesity and diabetes, were identifed as increasing risk of severe 
illness and death from COVID-19 early in the pandemic [43]. Indeed, participants of this 
study mentioned their body weight, insulin resistance and/or increased risk of developing 
diabetes and questioned whether this meant that their PCOS places them at higher risk for 
COVID-19. This lack of adequate information and risk-assessment regarding the potential 
higher risk of COVID-19 in individuals with PCOS has been highlighted as a concern for 
clinical practice [17] and was identifed as a cause of signifcant health anxiety for many 
participants in this study. 
Substantial additional distress was caused by restricted access to primary care and a 
pause in certain other specialist healthcare services relevant to PCOS, and the uncertainty of 
when these would be restored. Previous studies have highlighted that women with PCOS 
report feeling they have to fght for specialist healthcare for their condition [44]. The impact 
of this reduced capacity for PCOS treatment/management on the women in the present 
study ranged from frustration and disappointment, to distress and anxiety, as often women 
felt they had been left waiting with no certainty of when such services would be available 
again. There were also specifc worries that time may be running out for those awaiting 
fertility treatment. While this only applied to a couple of the 12 women in the present study, 
a recent UK survey also identifed that cancellation of fertility treatment during the COVID-
19 pandemic has caused signifcant psychological stress, feelings of isolation and weakened 
coping mechanisms in female fertility patients [45]. Some participants also mentioned that 
their healthcare professionals (e.g., primary care physicians) were an important source of 
support and that they were currently unable to easily contact them or have face-to-face 
appointments. Finally, participants highlighted the negative effect on their lifestyles due to 
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the COVID-19 pandemic and lockdown restrictions, including poor sleep, less access to 
healthy food and dietary supplements, and closure of exercise and leisure services. In such 
a patient group with a chronic condition for whom weight management is both highly 
needed, as a means to improve symptoms and/or to increase the chances of conceiving a 
child, and very challenging due to the underlying PCOS pathophysiology (e.g., vicious 
cycle between hyperandrogenism, central obesity and insulin resistance) [15,16], the impact 
of these changes on participants’ wellbeing cannot be underestimated. Indeed, several 
participants expressed concerns about gaining weight or disruption to ongoing weight loss 
management. As such, it is evident based on all these fndings that a multitude of factors 
have presented signifcant challenges to these participants’ mental wellbeing and have the 
potential for long-term deleterious consequences. 
In comparison to evidence gathered at a similar time for the impact of the COVID-19 
pandemic and lockdown restrictions on other populations with metabolic conditions, a 
qualitative study of adults with diabetes in Denmark reported similar challenges to self-
management of the condition, including access to exercise and emotional eating [46]. The 
fndings of this study also identifed anxiety relating to fear of the coronavirus and concerns 
about access to medication, and some participants reported that the lockdown gave them 
time to learn more about their condition. However, in contrast to the present study, the 
authors reported that some participants had experienced little change to their daily lives 
and were relatively unconcerned about the impact on their wellbeing. In another qualitative 
study in Ireland involving participants undergoing treatment for obesity, similar disruption 
to maintaining physical activity and dietary behaviours were reported, with a similar 
smaller number of positive changes to diet also noted [47]. In this study, the psychological 
impact was more evident and similar to the present study, with participants reporting 
anxiety and fear, both of the coronavirus and in relation to their weight loss goals [47]. 
Perhaps the most similar fnding however, can be found in studies of individuals with 
pre-existing mental health conditions, also conducted in the summer of 2020. For example, 
a UK qualitative interview study of 49 individuals with a range of mental illnesses [48] 
noted that some participants experienced a relief from external pressures during lockdown, 
but also reported a worsening of their mental health due to reduced access to mental 
healthcare services, and disruption to their normal life and coping strategies, including 
social support and exercise. A pre-print report of another UK study [49] also identifed 
some emotional relief from reduced social contact. However, these authors also report 
that isolation from social support, anxiety about the coronavirus and perceived lack of 
mental healthcare services, including worry about whether healthcare would be available 
in the future, all contributed to a deterioration in mental wellbeing in participants with 
pre-existing mental illness. 
Certain limitations of the present study must be acknowledged. The participants in 
this study had agreed to participate in both the “parent” cross-sectional research study 
and the present qualitative study, which were advertised via social media, including those 
of a PCOS charity (Verity, the UK PCOS charity) that offers online support forums and 
information for women with PCOS. As such, the study participants can be considered as 
motivated to contribute to research and may be more knowledgeable and/or engaged with 
their PCOS symptoms and treatment than other women with PCOS who do not seek out 
such information and support. However, this is common in such research studies, whilst 
the timely nature of the present research necessitated an expeditious recruitment method. 
Additionally, the large numbers of women who volunteered to participate in both studies 
suggests that the women with PCOS who are willing to contribute to research are not 
limited to only a highly motivated few. Moreover, as data were collected within a short 
timeframe during the frst UK COVID-19 related lockdown, fndings represent a snapshot 
of these women’s experiences at that time. Nevertheless, to our knowledge, this is the only 
study to explore the experience of the COVID-19 pandemic and lockdown restrictions for 
women with PCOS, and as such provides valuable insight which can be used to better 
support women with PCOS throughout this pandemic and beyond. 
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5. Conclusions and Implications for Practice 
To our knowledge, this is the frst qualitative study which captured the lived experi-
ence of women with PCOS during the COVID-19-related lockdown. The fndings of the 
present study, categorised into fve main themes as summarised in Figure 1, add to the 
growing body of evidence which highlights the struggles faced by women with PCOS, both 
in the UK and elsewhere (e.g., problems in accessing the primary and specialised healthcare 
services needed to treat the wide range of symptoms associated with this chronic condi-
tion). Indeed, the additional delays and uncertainty caused by the COVID-19 pandemic 
has caused signifcant distress to this frequently overlooked female patient population. 
In the UK, GPs are both the frst port of call for health queries and gatekeepers to spe-
cialised healthcare, and as such these frst-line primary healthcare practitioners should 
aim to encourage women with PCOS to continue to seek help when needed. Both GPs 
and specialist healthcare providers should make targeted efforts to keep such vulnerable 
patients informed about timescales for required treatments and specialist appointments. 
This further includes services such as fertility treatment, which may be both limited in 
availability for many and time sensitive. In the longer term, it appears clear that women 
with PCOS feel poorly understood and underserved by the current healthcare provision, as 
has been further highlighted during the COVID-19 pandemic. Given its prevalence, a fresh 
approach where women with PCOS are treated holistically and not as a disparate set of 
symptoms, along with better education of health professionals about the condition, would 
improve health outcomes and the quality of life for many women with PCOS, both under 
routine conditions and under emergency situations such as those posed by the COVID-19 
pandemic. 
Weight management is a pervasive challenge for the participants in this study, and 
the COVID-19 pandemic risked undoing the progress they had made. As indicated by 
the participants who found this pandemic to be an opportunity to research, re-evaluate 
and change their lifestyle, moving forward it is likely that behaviour change interventions 
would be extremely valuable to enable women with PCOS to make and sustain lifestyle 
change. This can be supported at scale by weight management services within primary care. 
The participants in this study demonstrated a worsening of their mental health overall. 
Participants were uncertain of how PCOS affected their COVID-19 risk, and this added 
to the anxiety and low mood or depression which was exacerbated by social isolation 
and the inability to employ their usual coping strategies, such as social support and 
physical activity. Given the high prevalence of depression, anxiety and other mental health 
disorders in women with PCOS, this is a patient group who would beneft from urgent and 
continued support from mental healthcare services [50], as well as clearer communication 
from primary care physicians regarding their ongoing risk as we move towards easing 
restrictions and “living with the coronavirus”. 
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